Poseida Therapeutics Profit Margin

Poseida Therapeutics posts a profit margin of -39.37% as of September 2024. That compares with -266.8% in the prior-year period — up 85.2% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Poseida Therapeutics's profit margin was -266.8%. The latest reading is -39.37% — a 85.2% year-over-year increase (period ending September 2024). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Poseida Therapeutics's -39.37% is lower that level. That is roughly 383.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Poseida Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -39.37% as of September 2024; use YoY and peer views to separate noise from signal.

Context for PSTX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Poseida Therapeutics's other metric pages and overview cover the third.